Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902171 | 1.00 | AR (0.32) | ARSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16994491 | 0.88 | JAK2 (0.33) | — | |
| SCHEMBL9901986 | 0.88 | JAK2 (0.33) | — | |
| SCHEMBL9901540 | 0.88 | KDM4E (0.39) | ARSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9905805 | 0.85 | P2RX7 (0.39) | — | |
| SCHEMBL9905806 | 0.85 | P2RX7 (0.39) | — | |
| SCHEMBL16994500 | 0.85 | P2RX7 (0.39) | — | |
| SCHEMBL9902819 | 0.83 | KDM4E (0.34) | ARSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9901674 | 0.83 | FPR2 (0.34) | — | |
| SCHEMBL16994512 | 0.81 | P2RX7 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102659-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2015-08-11 | — | — | US | claimed |
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2017-04-20 | — | — | US | disclosed |
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2649048-B1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9102659-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130338146-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2649048-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | Radikal Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012077108-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338146-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | AR 3356/4885SLC6A2 1840/4885SLC6A4 2370/4885 |
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOS1 | AR 3111/4885SLC6A2 1888/4885SLC6A4 2406/4885 |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | AR 3356/4885SLC6A2 1840/4885SLC6A4 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.